165
Views
18
CrossRef citations to date
0
Altmetric
Diagnostics

Validation of Strasbourg environmental exposure chamber (EEC) ALYATEC® in mite allergic subjects with asthma

, MD, PhD, , MD, , MD, , MD, , MD, , BSc, , BSc, , BSc, , PhD, , PhD & , MD show all
Pages 140-148 | Received 18 Oct 2018, Accepted 22 Dec 2018, Published online: 28 Mar 2019

References

  • Bornemann R, Hagemeister K, Bresser H-G, Hamelmann E. Allergy and school: nothing to be sneezed at!: a primary school project in Bielefeld, Germany, on epidemiology and health promotion in allergic diseases. Allergo J Int 2016;25:201–209.
  • Holgate ST. The epidemic of allergy and asthma. Nature 1999;402:B2–B4.
  • D'Amato G, Vitale C, Lanza M, Molino A, D'Amato M. Climate change, air pollution, and allergic respiratory diseases: an update. Curr Opin Allergy Clin Immunol 2016;16:434–440.
  • Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006;355:2226–2235.
  • Diamant Z, Gauvreau GM, Cockcroft DW, Boulet L-P, Sterk PJ, de Jongh FHC, Dahlén B, O’Byrne PM. Inhaled allergen bronchoprovocation tests. J Allergy Clin Immunol 2013;132:1045–1055.e6. doi:10.1016/j.jaci.2013.08.023.
  • Boulet L-P, Gauvreau G, Boulay M-E, O’Byrne P, Cockcroft DW. Clinical Investigative Collaboration, Canadian Network of Centers of Excellence AllerGen. The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy 2007;62:1101–1110. doi:10.1111/j.1398-9995.2007.01499.x.
  • Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N, Leynadier F, et al. The role of allergen challenge chambers in the evaluation of anti‐allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006;6:31.
  • Lueer K, Biller H, Casper A, Windt H, Mueller M, Badorrek P, Haefner D, et al. Safety, efficacy and repeatability of a novel house dust mite allergen challenge technique in the Fraunhofer allergen challenge chamber. Allergy 2016;71:1693–1700.
  • Horak F, Stübner U, Zieglmayer R, Harris A. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109:956–961. doi:10.1067/mai.2002.124657.
  • Krug N, Loedding H, Hohlfeld JM, Larbig M, Buckendahl A, Badorrek P, Geldmacher H, et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy 2003;33:1667–1674. doi:10.1111/j.1365-2222.2003.01810.x.
  • Pfaar O, Calderon MA, Andrews CP, Angjeli E, Bergmann KC, Bønløkke JH, de Blay F, et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy 2017;72:1035–1042. doi:10.1111/all.13133.
  • Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D. European Community Respiratory Health Survey I. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy 2007;62:301–309.
  • Calderón MA, Linneberg A, Kleine-Tebbe J, De Blay F, Hernandez Fernandez de Rojas D, Virchow JC, Demoly P. Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol 2015;136:38–48. doi:10.1016/j.jaci.2014.10.012.
  • Platts-Mills TA, Vervloet D, Thomas WR, Aalberse RC, Chapman MD. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997;100:S2–S24. doi:10.1016/S0091-6749(97)70292-6.
  • Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, Cowan JO, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003;349:1414–1422.
  • ANSM authorisation for ALK and Stallergene, 31st December 2017, http://ansm.sante.fr/Decisions/Autorisations-APSI.
  • de Blay F, Heymann PW, Chapman MD, Platts-Mills TA. Airborne dust mite allergens: comparison of group II allergens with group I mite allergen and cat-allergen Fel d I. J Allergy Clin Immunol 1991;88:919–926.
  • Barnig C, Purohit A, Casset A, Sohy C, Lieutier-Colas F, Sauleau E, de Blay F. Nonallergic airway hyperresponsiveness and allergen-specific IgE levels are the main determinants of the early and late asthmatic response to allergen. J Investig Allergol Clin Immunol 2013;23:267–274.
  • Casset A, Purohit A, Birba E, Chenard M-P, Uring Lambert B, Bahram S, Meyer P, et al. Bronchial challenge test in asthmatics sensitized to mites: role of particle size in bronchial response. J Aerosol Med 2007;20:509–518. doi:10.1089/jam.2007.0591.
  • Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy 2013;43:881–888. doi:10.1111/cea.12121.
  • Zielen S, Trischler J, Schubert R. Lipopolysaccharide challenge: immunological effects and safety in humans. Expert Rev Clin Immunol 2015;11:409–418. doi:10.1586/1744666X.2015.1012158.
  • Sohy C, Pons F, Casset A, Chesnard M-P, Lieutier-Colas F, Meyer P, Pauli G, et al. Low-dose endotoxin in allergic asthmatics: effect on bronchial and inflammatory response to cat allergen. Clin Exp Allergy 2006;36:795–802. doi:10.1111/j.1365-2222.2006.02500.x.
  • Devillier P, Le Gall M, Horak F. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. Allergy 2011;66:163–169. doi:10.1111/j.1398-9995.2010.02473.x.
  • Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Devillier P, Montagut A, Mélac M, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471–477, 477.e1. doi:10.1016/j.jaci.2009.06.006.
  • Didier A, Malling H-J, Worm M, Horak F, Jäger S, Montagut A, André C, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338.
  • Boulet LP, Gauvreau G, Boulay ME, O'Byrne PM, Cockcroft DW. Allergen-induced early and late asthmatic responses to inhaled seasonal and perennial allergens. Clin Exp Allergy 2015;45:1647–1653. doi:10.1111/cea.12587.
  • de Blay F, Doyen V, Lutz C, Godet J, Barnig C, Qi S, Braun JJ. A new, faster, and safe nasal provocation test method for diagnosing mite allergic rhinitis. Ann Allergy Asthma Immunol 2015;115:385–390. Nov
  • Wood RA, Eggleston PA, Lind P, Ingemann L, Schwartz B, Graveson S, Terry D, et al. Antigenic analysis of household dust samples. Am Rev Respir Dis 1988;137:358–363.
  • Luczynska CM, Li Y, Chapman MD, Platts-Mills TA. Airborne concentrations and particle size distribution of allergen derived from domestic cats (Felis domesticus). Measurements using cascade impactor, liquid impinger, and a two-site monoclonal antibody assay for Fel d I. Am Rev Respir Dis 1990;141:361–367. doi:10.1164/ajrccm/141.2.361.
  • de Blay F. Provocation tests as measure of efficacy and dosage. Allergy 2011;66:47–49.
  • Jacobs RL, Andrews CP, Ramirez DA, Rather CG, Harper N, Jimenez F, Martinez H, et al. Symptom dynamics during repeated serial allergen challenge chamber exposures to house dust mite. J Allergy Clin Immunol 2015;135:1071–1075.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.